Mirum Pharmaceuticals has been granted a patent for methods of treating cholestasis in liver disease patients by administering an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) at a dose of at least 10 µg/kg/day. Another claim involves treating cholestatic pruritus in Alagille Syndrome patients with maralixibat at a dose of 400-800 µg/kg/day. GlobalData’s report on Mirum Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Mirum Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Mirum Pharmaceuticals, Molecular diagnosis biomarkers was a key innovation area identified from patents. Mirum Pharmaceuticals's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of cholestatic pruritus in alagille syndrome with maralixibat

Source: United States Patent and Trademark Office (USPTO). Credit: Mirum Pharmaceuticals Inc

A recently granted patent (Publication Number: US11918578B2) discloses a method for treating cholestatic pruritus in individuals with Alagille Syndrome (ALGS) by administering maralixibat in specific dosages. The method involves administering maralixibat in a liquid pharmaceutical composition ranging from about 0.001 mg/mL to about 16 mg/mL, at a dosage of about 400 µg/kg/day to about 800 µg/kg/day. The administration of maralixibat is recommended once daily for a period of at least 18 weeks, with options to extend the treatment duration up to 3 years.

Furthermore, the patent claims specify that the method is particularly suitable for pediatric subjects aged at least 1 year, with the administration of maralixibat recommended prior to food ingestion. The liquid pharmaceutical composition containing maralixibat can be administered orally as an oral solution or an aqueous solution, with a concentration of about 10 mg/mL of maralixibat. The method provides a detailed protocol for the effective treatment of cholestatic pruritus in ALGS patients, offering specific dosage ranges and administration guidelines for optimal therapeutic outcomes.

To know more about GlobalData’s detailed insights on Mirum Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies